权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Tobacco Craving in Smokers with Schizophrenia

精神分裂症吸烟者对烟草的渴望

基本信息

批准号：
9040132
负责人：
HEIDI J WEHRING
金额：
$ 17.4万
依托单位：
UNIVERSITY OF MARYLAND BALTIMORE
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-04-15 至 2018-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9040132
关键词：
Abstinence Alcohol or Other Drugs use Antibiotics Antismoking Award Biometry Carbon Monoxide Characteristics Cigarette Clinical Trials Cotinine Cues Data Data Analyses Development Diagnosis Disease Effectiveness Emotional Emotions Environment Environmental Impact Exhibits Fostering Future General Population Goals Health Intake Intervention K-Series Research Career Programs Measurement Measures Mental disorders Mentored Patient-Oriented Research Career Development Award Mentors Minocycline Mission Moods Morbidity - disease rate National Institute of Drug Abuse Nicotine Nicotine Withdrawal Nitric Oxide Patient Self-Report Persons Pharmaceutical Preparations Pharmacology Physiological Pilot Projects Placebos Play Population Principal Investigator Psyche structure Public Health Publishing Reporting Research Research Design Research Personnel Research Proposals Research Support Research Training Rewards Risk Role Safety Sampling Schizophrenia Smoke Smoker Smoking Smoking Behavior Smoking Cessation Intervention Strategic Planning Substance Addiction Substance Use Disorder Substance abuse problem Substance of Abuse Techniques Testing Time Tobacco Tobacco Dependence Training United States National Institutes of Health Urine Work attenuation base career cigarette smoking craving dual diagnosis effective intervention experience improved innovation mortality novel novel strategies programs response severe mental illness skills smoking cessation smoking prevalence smoking relapse social substance abuse treatment treatment trial virtual reality

项目摘要

DESCRIPTION (provided by applicant): Cigarette smoking continues to have a major impact on morbidity and mortality, despite attempts to educate smokers and to improve smoking cessation interventions. Persons with schizophrenia are at greater risk for deleterious effects than the general population, due to the large percentage of persons with schizophrenia (60%-70%) who smoke cigarettes. This subset of the population are more likely to be heavier smokers, are three times more likely to start and five times less likely to quit smoking than people in the general population. Craving is a significant barrier to cessation, and may be experienced differently by persons with schizophrenia compared to the general population. This K23 mentored-research patient oriented career development award, submitted by Principal Investigator Dr. Heidi Wehring, focuses on craving and testing a novel craving intervention for smokers with schizophrenia. This focus fits well within the NIDA 5-Year Strategic Plan regarding substance abuse and treatment in persons with co-occurring mental disorders, and is consistent with the NIH mission to foster discoveries, innovative research strategies, and their applications by supporting research in the understanding of mental, addictive, and physical disorders. Dr. Wehring has a long-term career goal of becoming an independent investigator of treatment research for persons with schizophrenia who are dually diagnosed with a substance use disorder, specifically to determine novel approaches to the challenge of nicotine cessation. This may be done through using research to better define craving, abstinence, and other factors that may be targeted by pharmacological or nonpharmacological interventions. This K23 proposal has both research and training aims and goals. Short-term goals include contributions to the field of craving research in schizophrenia and Dr. Wehring's development as an independent investigator. These goals will be accomplished by a research proposal aiming to further define components of tobacco craving in smokers with schizophrenia, to determine the effects of minocycline on cigarette craving and smoking intensity via a pilot study, and to determine the relationship between changes in craving, smoking intensity, and responses to individualized cues/triggers to craving in smokers with schizophrenia. Dr. Wehring will be mentored by Dr. Deanna Kelly, an expert in schizophrenia, clinical trials, and dual diagnosis, and Dr. Stephen Heishman, an expert in tobacco, nicotine pharmacology, and cue-elicited craving, and will benefit from the support of Consultants Dr. Robert McMahon, an expert in biostatistics and research design and A. Eden Evins, with expertise in nicotine use in schizophrenia. Dr. Wehring will also pursue coursework during the K award period to increase skills and develop expertise necessary to become an independent investigator. This project will provide pilot data to build future research focusing on the development of interventions for smoking cessation in persons with schizophrenia. This is of paramount importance, as the understanding of underlying aspects of substance use will be instrumental in creation of effective interventions.

描述（由申请人提供）：尽管试图教育吸烟者并改善戒烟干预措施，吸烟仍然对发病率和死亡率产生重大影响。精神分裂症患者比一般人群面临更大的有害影响风险，因为很大比例的精神分裂症患者（60%-70%）吸烟。这部分人群更有可能成为重度吸烟者，开始吸烟的可能性是普通人群的三倍，戒烟的可能性是普通人群的五倍。渴望是戒烟的一个重要障碍，与一般人群相比，精神分裂症患者的体验可能不同。这个由首席研究员Heidi Wehring博士提交的K23指导研究患者导向的职业发展奖项，专注于对精神分裂症吸烟者的渴望和测试一种新的渴望干预。这一重点与NIDA关于同时发生精神障碍的人的药物滥用和治疗的5年战略计划非常吻合，并且与NIH通过支持对精神、成瘾和身体疾病的理解研究来促进发现、创新研究策略及其应用的使命是一致的。Wehring博士的长期职业目标是成为精神分裂症患者治疗研究的独立调查员，这些精神分裂症患者被双重诊断为物质使用障碍，特别是确定应对尼古丁戒烟挑战的新方法。这可以通过研究来更好地定义渴望、禁欲和其他可能通过药物或非药物干预的因素来实现。这个K23提案有研究和培训的目的和目标。短期目标包括对精神分裂症的渴望研究领域做出贡献，以及韦林博士作为一名独立研究者的发展。这些目标将通过一项研究计划来实现，该研究计划旨在进一步确定精神分裂症吸烟者对烟草渴望的组成部分，通过一项试点研究确定二甲胺四环素对香烟渴望和吸烟强度的影响，并确定精神分裂症吸烟者对烟草渴望的变化、吸烟强度和对个性化线索/触发因素的反应之间的关系。Wehring博士将接受精神分裂症、临床试验和双重诊断方面的专家Deanna Kelly博士和烟草、尼古丁药理学和线索诱导渴望方面的专家Stephen Heishman博士的指导，并将受益于生物统计学和研究设计方面的专家Robert McMahon博士和精神分裂症中尼古丁使用方面的专家A. Eden Evins的支持。Wehring博士还将在K奖期间学习课程，以提高技能和发展成为独立调查员所需的专业知识。该项目将提供试点数据，以建立未来的研究，重点是制定精神分裂症患者戒烟干预措施。这一点至关重要，因为了解药物使用的潜在方面将有助于制定有效的干预措施。